PublicXPrivate
PublicXPrivate
In March 2000, deCODE Genetics filed its registration statement, immediately electronically accessible, with the U.S. Securities and Exchange Commission. deCODE was planning to go public sometime in May of that year, offering its stock for sale on the tech-centric NASDAQ exchange. So began a new phase of the author's research on promising genomics in a lavaXland which now included that most volatile of territories in that most volatile of times: the U.S. stock market on the millennium's cusp. In early March 2000, the promising biotechnology economy was in full surge. deCODE was probably hoping that they could ride it to a quick and gloriously lucrative initial public offering. Things did not turn out that way. The biomarket crash—or dip, or “necessary correction”—happened in the middle of the author's March 2000 visit to Iceland, and it sparked some optimism among those opposed to an Icelandic genomic future centralized in deCODE and the Health Sector Database.
Keywords: Iceland, deCODE Genetics, NASDAQ, stock market, biotechnology, lucrative public offering, Health Sector Database, genomics
California Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.
Please, subscribe or login to access full text content.
If you think you should have access to this title, please contact your librarian.
To troubleshoot, please check our FAQs, and if you can't find the answer there, please contact us.
